Shoulder Innovations (NYSE:SI) Major Shareholder Sells $15,404.22 in Stock

Shoulder Innovations, Inc. (NYSE:SI) major shareholder Healthcare Holding B.V. Gilde sold 681 shares of Shoulder Innovations stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $22.62, for a total transaction of $15,404.22. Following the completion of the transaction, the insider owned 2,187,110 shares of the company’s stock, valued at $49,472,428.20. This represents a 0.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Friday, August 21st, Healthcare Holding B.V. Gilde sold 20,516 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.61, for a total transaction of $463,866.76.
• On Thursday, August 20th, Healthcare Holding B.V. Gilde sold 3,900 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total value of $88,140.00.
• On Thursday, August 6th, Healthcare Holding B.V. Gilde sold 2,095 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.60, for a total value of $47,347.00.
• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.64, for a total transaction of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.77, for a total transaction of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.73, for a total transaction of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The stock was sold at an average price of $23.36, for a total transaction of $659,803.20.

Shoulder Innovations Price Performance

Shares of SI opened at $22.45 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 10.71 and a quick ratio of 8.92. Shoulder Innovations, Inc. has a 1-year low of $10.92 and a 1-year high of $24.59. The stock has a market cap of $467.39 million and a PE ratio of -11.69. The firm has a fifty day moving average price of $21.19 and a 200 day moving average price of $16.73.

Shoulder Innovations (NYSE:SI) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Shoulder Innovations had a negative return on equity of 23.61% and a negative net margin of 58.33%.The firm had revenue of $17.18 million for the quarter. As a group, sell-side analysts anticipate that Shoulder Innovations, Inc. will post -1.9 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Weiss Ratings raised Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. UBS Group raised their target price on shares of Shoulder Innovations from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. BTIG Research lifted their target price on shares of Shoulder Innovations from $24.00 to $26.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $25.00 price target (up from $19.00) on shares of Shoulder Innovations in a research report on Friday, August 7th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Shoulder Innovations currently has an average rating of “Moderate Buy” and an average price target of $25.50.

Institutional Trading of Shoulder Innovations

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Shoulder Innovations during the 3rd quarter worth approximately $28,000. Compass Financial Management LLC purchased a new stake in shares of Shoulder Innovations during the second quarter worth approximately $30,000. Rhumbline Advisers acquired a new stake in shares of Shoulder Innovations during the third quarter worth $54,000. California State Teachers Retirement System lifted its holdings in shares of Shoulder Innovations by 412.4% during the second quarter. California State Teachers Retirement System now owns 2,941 shares of the company’s stock worth $60,000 after purchasing an additional 2,367 shares during the period. Finally, Wells Fargo & Company MN grew its position in Shoulder Innovations by 66.3% in the 4th quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock valued at $75,000 after buying an additional 2,094 shares during the last quarter.

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.